Skip to main content

Advertisement

SpringerLink
Log in

Cytoplasmic sequestration of wild-type p53 in a patient with therapy-related resistant AML: first report

  • Case Report
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

p53 inactivation is a key factor in human tumorigenesis and chemotherapy resistance. The traditionally described mechanisms of p53 inactivation in acute myeloid leukemia (AML) include TP53 mutations and abrogation of p53 pathway. Malfunction of wild-type (wt) p53, due to its cytoplasmic mislocalization, has been described, thus far, only in solid tumors. Herein, we present a patient with therapy-related resistant AML, monosomal karyotype, wt TP53, and cytoplasmic sequestration of p53 protein. Proposed mechanisms of p53 mislocalization and their probable clinical and therapeutic implications are discussed. In view of the relative rareness of TP53 mutations in AML, the cytoplasmic sequestration of p53 protein offers an additional inactivating mechanism, which might be more frequent than currently diagnosed. This notion warrants confirmation by prospective studies in large cohorts of patients. We recommend that evaluation of p53 subcellular localization and function should be included in the diagnostic work-up of AML with wt p53.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer. 2004;4:106–17.

    Article  PubMed  CAS  Google Scholar 

  2. Green DR, Kroemer G. Cytoplasmic functions of the tumor suppressor p53. Nature. 2009;458:1127–30.

    Article  PubMed  CAS  Google Scholar 

  3. Tasdemir E, Maiuri MC, Galluzzi L, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biology. 2008;10:676–87.

    Article  CAS  Google Scholar 

  4. Peller S, Yona R, Kopilova Y, et al. Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia. Genes Chromosomes Cancer. 1998;21:2–7.

    Article  PubMed  CAS  Google Scholar 

  5. Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood. 1994;84:2391–411.

    PubMed  CAS  Google Scholar 

  6. Pedersen-Bjergaard J, Andersen MT, Andersen MK. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2007; 392–397.

  7. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with complex aberrant karyotype. Leukemia. 2008;22:1539–41.

    Article  PubMed  CAS  Google Scholar 

  8. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP. Human p53 gene localized to short arm of chromosome 17. Nature. 1986;319:783–4.

    Article  PubMed  CAS  Google Scholar 

  9. O’Brate A, Giannakakou P. The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist Updat. 2003;6:313–22.

    Article  PubMed  Google Scholar 

  10. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9:862–73.

    Article  PubMed  CAS  Google Scholar 

  11. Utama B, Shen YH, Mitchell BM, et al. Mechanisms for human cytomegalovirus-induced cytoplasmic p53 sequestration in endothelial cells. J Cell Sci. 2006;119:2457–67.

    Article  PubMed  CAS  Google Scholar 

  12. Bueso-Ramos CE, Yang Y, deLeon E, et al. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993;82:2617–23.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Belinson Hospital, Rabin Medical Center, 49100, Petach-Tikva, Israel

    Miron Prokocimer

  2. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Miron Prokocimer

  3. The Laboratory of Hematology, Assaf-Harofeh Medical Center, Zerifin, Israel

    Shoshana Peller

Authors
  1. Miron Prokocimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shoshana Peller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miron Prokocimer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prokocimer, M., Peller, S. Cytoplasmic sequestration of wild-type p53 in a patient with therapy-related resistant AML: first report. Med Oncol 29, 1148–1150 (2012). https://doi.org/10.1007/s12032-011-9916-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9916-x

Keywords

Search

Navigation